Davenport & Co
CADL icon

Davenport & Co’s Candel Therapeutics CADL Stock Holding History

Davenport & Co’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$109K Buy
10,400
+200
+2% +$2.22K ﹤0.01% 1372
2026
Q2 		$105K Buy
+10,200
New +$77K ﹤0.01% 1342

Other funds holding CADL

Tanager Wealth Management
Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Financial Consulate
Financial Consulate Hunt Valley, Maryland $899M AUM 14.82% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Davenport & Co's CADL Position: Q3 2026 in Review

Davenport & Co increased its Candel Therapeutics (CADL) stake by 2% in Q3 2026, buying an estimated $2.22K and bringing the position to 10,400 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1372.

Davenport & Co first reported a position in CADL in Q2 2026 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Davenport & Co held 10,400 shares of Candel Therapeutics worth $109K as of Q3 2026.
  • Davenport & Co bought 200 Candel Therapeutics shares in Q3 2026, an estimated $2.22K.
  • Candel Therapeutics made up ﹤0.01% of Davenport & Co's portfolio in Q3 2026, its #1372 holding.
  • Davenport & Co first reported a position in Candel Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.